S3934

The Medical Nutrition Therapy Act of 2026 (S3934) expands Medicare Part B coverage for medical nutrition therapy (MNT) services provided by registered dietitians and nutrition professionals. This expansion includes a broader range of diseases beyond diabetes and renal disease, such as obesity, hypertension, and dyslipidemia. This directly increases the addressable market for MNT services, creating new revenue opportunities for healthcare providers and companies involved in nutrition services and products. The bill's referral to the Committee on Finance, with Senator Collins (R-ME) as a sponsor, indicates moderate legislative momentum, as Senator Collins is a senior member of the Senate Appropriations Committee, though not the Finance Committee. The money trail for this bill flows directly from Medicare Part B reimbursements to healthcare providers employing or contracting with registered dietitians. This means increased revenue for large healthcare systems, integrated health plans, and pharmacy chains that offer or can easily integrate MNT services. Companies like OptumHealth, a subsidiary of UnitedHealth Group ($UNH), which provides care delivery and health services, are positioned to capture a significant portion of this funding. Pharmacy benefit managers and retail pharmacy chains such as CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) that are expanding into health services will also benefit from increased patient traffic and service offerings. Additionally, companies providing medical foods or specialized nutritional supplements, such as Nestle Health Science (part of Nestle, $NSRGY), will see an indirect increase in demand as MNT becomes more accessible. Historically, similar expansions of Medicare coverage have led to increased utilization and revenue for the covered services. For example, when Medicare Part D was implemented in 2006, pharmaceutical companies saw a significant increase in prescription drug sales. While not a direct parallel, the expansion of covered services under Medicare consistently drives market growth for the beneficiaries. More recently, the expansion of telehealth coverage during the COVID-19 pandemic led to a sustained increase in demand for virtual care platforms and services, benefiting companies like Teladoc Health ($TDOC) and Amwell ($AMWL). Specific winners include UnitedHealth Group ($UNH) through its Optum division, which will see increased demand for its health services. CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) will benefit from increased patient engagement in their health clinics and retail pharmacies. Companies like Omnicell ($OMCL), which provides medication adherence and pharmacy automation solutions, may see indirect benefits from increased patient engagement in chronic disease management. There are no direct losers from this bill; rather, it represents a market expansion. Next steps involve the bill being considered by the Senate Finance Committee. If approved, it would then move to the full Senate for a vote. If passed by the Senate, it would then go to the House for consideration. The timeline for passage is uncertain, but committee referral is the first step in the legislative process. If enacted, implementation would likely follow within 12-18 months, leading to a gradual increase in MNT utilization.